Purpose: We investigated whether acromegaly has been diagnosed earlier at the Niigata Medical and Dental University Hospital. Methods: Patients with acromegaly (n = 81) who underwent their first transsphenoidal surgery from 2006 to 2015 were reviewed. Two groups were compared: those who underwent surgery between 2006 and 2010 (n = 35) and those who underwent surgery between 2011 and 2015 (n = 46). We compared clinical features and serum levels of the growth hormone (GH) and insulin-like growth factor-1 (IGF-1), hypertension (HT) and diabetes mellitus (DM) prevalence between the two groups. Results: Compared with the early group, microadenomas (<10 mm) were more prevalent in the late group (0% vs. 15.2%, p < .05). Serum IGF-1 standard deviation score (SDS) was significantly lower in the late group (8.57 ± 2.50 vs. 6.44 ± 2.30, p < .001). In both groups, mean IGF-1 SDS was significantly lower in patients without DM than in those with DM (6.9 ± 2.6 vs. 8.3 ± 2.4, p = .02). Logistic regression analysis showed that serum GH and IGF-1 levels were significantly higher in patients with DM than in those without DM. Conclusion: Regarding operated cases of GH-producing pituitary adenoma, acromegaly clinical manifestations tended to be milder at diagnosis in later years of the decade, and acromegaly was diagnosed at lower IGF-1 levels and in smaller lesions. Further study is mandatory for the generalization of this trend.
Introduction
Acromegaly is often complicated by HT, DM, or other comorbidities. Patients with acromegaly have a reduced life expectancy because of cardiovascular, cerebrovascular, and respiratory diseases [1] . Tumor size increases insidiously until typical features develop, at which time it may be quite large [2] .
Transsphenoidal surgery is indicated as the first-line therapy [3, 4] . The biochemical remission rate following surgery performed by an experienced surgeon is around 70% [5] . Favorable postoperative outcomes are likelier with a smaller tumor, lower Knosp grade, and lower preoperative GH and IGF-1 levels [6] . Patients with incomplete cure require medications and/or radiation therapy [3, 7, 8] . Better surgical results and subsequent patient outcomes can be expected if GH-secreting pituitary adenomas are detected earlier in the course of the disease. However, there are very few data available to determine whether these tumors are increasingly being detected at an earlier stage.
The Niigata Prefecture of Japan has a population of approximately 2.3 million. Most residents of this prefecture with pituitary tumors are treated surgically at the Department of Neurosurgery, Niigata University Medical and Dental Hospital. Recently, we noticed that our patients with acromegaly tended to have milder clinical features compared with those presenting in earlier years [9] . Thus, we investigated changes in the clinical characteristics of patients with acromegaly between the early and late years of the past decade. This study is intended to clarify the trends in disease detection and to determine the clinical significance of the results. Various specialty physicians suspected the diagnosis: internal medicine (25 patients), neurosurgery (18) , neurology (6), otorhinolaryngology (6), orthopedic surgery (4), general surgery (3), cardiology (3), dentistry (3), gynecology (2), anesthesiology (1), cardiovascular surgery (1), ophthalmology (1), psychiatry (1) and unknown (1) . Six cases were diagnosed during a regular health examination.
Subjects and methods

Patients
From patient charts, clinical and hormonal data were retrospectively collected, which included presenting complaints, symptom durations, basal serum GH and IGF-1 levels at diagnosis, comorbidities, and postoperative course. Radiological findings were recorded including the pituitary tumors size and heel-pad thickness at diagnosis.
The time from the appearance of initial symptoms (nose, hands, or feet enlargement in most cases) noted until the diagnosis of acromegaly was based on interview.
Patients under treatment for either or both conditions at the time of acromegaly diagnosis and those with untreated diabetes (DM) and/or hypertension (HT), but who met the diagnostic criteria [10, 11] , were considered as having DM and/or HT.
Measurements
Serum GH levels were measured by an immuno-enzymometric assay (Tosoh Corporation, Tokyo, Japan) using a uniform recombinant human GH standard [7, 12] . Reference values of GH were <0.64 ng/ml in males and 0.11-3.90 ng/ml in females.
Serum IGF-1 levels were measured by an immunoradiometric assay (Daiichi, Fujifilm RI Pharma Co., Ltd., Tokyo, Japan). Isojima et al. established age-and gender-specific IGF-I reference values for Japanese population [12] , based on which serum IGF-1 levels were converted to IGF-1 SDS.
Statistical analysis
Two groups of patients were compared: those who underwent surgery between 2006 and 2010 (n = 35) and those who underwent surgery between 2011 and 2015 (n = 46).
We compared clinical features and serum GH and IGF-1 levels between the two groups. Where indicated, data are represented as mean ± standard deviation (SD) and were statistically compared using a t-test, and categorical variables are reported as percentages and compared using Fisher's exact test. Correlation between serum IGF-1 values and the operation period was examined using linear approximation.
To assess the association between serum GH and IGF-1 values at diagnosis and clinical features in patients, we examined differences between GH and IGF-1 levels and DM or HT status using a t-test. Odds ratio with 95% confidence intervals for DM and HT risk were calculated for several variables (age, sex, GH levels, IGF-1 levels, and SDS) by univariate logistic regression analysis using SPSS ver. 22.0 for Windows (SPSS Inc., Chicago, Illinois). P < .05 was considered statistically significant.
One woman in the early group with a >+17 SD baseline GH value (using GH value as an outlier) and one aged >75 years in the late group whose IGF-1 SDS could not be calculated were excluded from our statistical analyses.
Results
Differences in clinical characteristics
As shown in Table 1 , sex, age at diagnosis, and time from symptom onset to diagnosis did not differ between the two groups. However, fewer cases were diagnosed in men <40 years in the early period (1/12, 8.3%) than in the late (8/20, 40%).
Patients with a <5 ng/ml serum GH value were seen more frequently in the late period (11.4% vs. 26.1%). No significant difference was seen in the ratio of patients with <22 mm heel-pad thickness for the two groups (p = .204), but in the linear approximation, heel-pad thickness and operation date showed a weak negatively correlation (r = À0.29, p = .013) (Fig. 1) .
Although DM or HT prevalence was lower in the late group than in the early group, the difference was insignificant (DM: 38.2% vs. 28.3%; HT: 37.1% vs. 30.4%).
Microadenomas were found in seven patients in the late group. This difference was significant (p = .037).
Patients incidentally diagnosed with pituitary adenoma by MRI were more frequent in the late group (14.7% vs. 30.4%). Presenting complaints unrelated to GH-producing adenoma (e.g., health examination, trauma, common cold, spinal cord disease, forgetfulness, suicide attempt, Bell's palsy, and so on) were also more frequent in the late group (26.5% vs. 45.7%), although the difference was insignificant.
Eight of the 46 patients (17.4%) in the late group received additional postoperative treatment (cabergoline, 7; cabergoline + lan reotide + radiation, 1) as did nine of the 35 patients (28.5%) in the early group (cabergoline, 2; gamma knife, 3; octreotide, 1; bromocriptine, 4, with some overlap).
Postoperative normalization of age-related IGF-1 levels (within + 2 SD) and suppression of serum GH < 1.0 ng/ml after a 75-g OGTT or a random GH < 1.0 ng/ml occurred in 72.8% of the total sample, 
Differences in preoperative serum GH and IGF-1 levels
The mean GH level was 30.1 ± 47.3 ng/ml and 18.6 ± 22.1 ng/ml in the early and late groups, respectively (p = .152). IGF-1 SDS was significantly lower in the late group (6.4 ± 2.3 vs. 8.6 ± 2.5, p < .001) (Fig. 2) .
A moderately negative correlation was observed between serum IGF-1 SDS at the time of diagnosis and operation date (r = À0.415, p < .001) (Fig. 3) .
GH, IGF-1, and comorbidities
Mean GH and IGF-1 SDS at diagnosis were significantly higher in patients with DM than in those without DM (39.9 ± 55.2 vs.
16.3 ± 17.1, p = .006 and 8.3 ± 2.4 vs. 6.9 ± 2.6, p = .02, respectively). However, these results did not differ significantly between patients with and without HT (23.5 ± 31.0 vs. 23.5 ± 37.6, p = .999 and 7.9 ± 3.1 vs 7.1 ± 2.3, p = .172, respectively). By the univariate logistic regression analysis, higher GH and IGF-1 SDS were significantly associated with an increased risk of DM (p = .029 and .026, respectively), whereas age was the only significant risk factor for HT (p = .001) ( Table 2 ).
Discussion
Over the past decade, we found several differences in patients with acromegaly. Among patients in the late group, microadenomas were more frequent, soft tissue thickening was milder, fewer patients had DM or HT, and serum IGF-1 SDS at diagnosis was lower. We also noted that higher IGF-1 and GH levels were associated with a higher DM risk.
Few studies have examined changes in presenting clinical features of acromegaly over time [13] [14] [15] [16] . Although some have noted that the diagnosis is made sooner after symptom onset [13] or there is less use of radiation therapy [13, 14] , none have demonstrated that the disease is definitely being diagnosed at an earlier stage. The actual duration of the disease before diagnosis is very difficult to determine, as it depends completely on the patients' Fig. 1 . Heel-pad thickness at diagnosis and the date of operation for acromegaly. Fig. 2 . Preoperative serum growth hormone (GH) levels and standard deviation scores for serum IGF-1 levels (IGF-1 SDS) in patients with acromegaly treated early vs. late in the past decade. OR = Odds ratio, CI = confidence interval, GH = growth hormone, IGF-1 = insulin-like growth factor-1. n = 81. * One outlier value (>+17 SD) is excluded.
subjective experience, which is not useful in statistical studies. On the other hand, information on the age at diagnosis is available from multiple studies [14, 16] (Table 3) . There are several explanations regarding differences between the early and late groups in our study, despite the small sample size encompassing a period of only 10 years.
1) Marked advances in diagnostic tools: Highly sensitive GH
assays [17, 18] , diagnosis of acromegaly with apparently normal GH but elevated IGF-1 levels [19, 20] , and introduction of 3T or greater high-resolution MRI [21] [22] [23] have all contributed to our early diagnosis. 2) Education and information access: The physicians' specialties in our study varied widely. Furthermore, with medical information disseminated on the Internet, the public may be more aware of the disease. In recent years, we have occasionally encountered self-referred patients. intractable disease list in Japan [25] . With this listing, public assistance became available to patients with acromegaly, achieved other than ordinary health insurance. This action reduced their out-of-pocket costs so that they had access to good treatment, particularly an early operation.
The combination of these factors may be unique to Japan. It remains to be seen if the findings in our study would be replicated in other countries.
Our results showed that in patients with acromegaly, high IGF-1 and GH serum levels are correlated with DM but not with HT. In patients with acromegaly, most previous studies have regarded a high IGF-1 level as a predictor of DM and HT [14, [26] [27] [28] .
Our results are consistent with previous studies for DM comorbid with acromegaly, but inconsistent for HT comorbidity. This may be due to ethnic differences, but to the best of our knowledge, data comparing Asians with non-Asians in this regard are not available elsewhere. Conversely, HT often persists after successful treatment of acromegaly [29] . Therefore, essential HT prevalence in different patient samples may account for different findings.
In this study, we showed that patients with acromegaly tend to be diagnosed with smaller lesions, lower GH and IGF-1 levels, and less complications in later years. High IGF-1 and GH levels were closely correlated with DM in our patients with GH-producing pituitary adenoma (GHoma). These findings suggest that earlier diagnosis of and medical intervention for acromegaly may improve the outcome of comorbid DM and the overall outcome of acromegaly in the near future, although there is no statistical difference in remission rate at the present time. Clinicians should always consider this disease (GHoma with/without overt acromegaly) while providing medical care for DM or other complications that can occur due to acromegaly.
Are GH-producing adenomas being detected earlier? Our study answers this question in the affirmative. Further progress in earlier diagnosis may possibly lead to a better outcome for patients with GHoma.
Conclusion
Our study, despite comprising a small series of patients in a single tertiary referral center, showed that in GHoma operated cases at our institution, clinical manifestations of acromegaly were milder at diagnosis in later years of the decade, and acromegaly was diagnosed at lower IGF-1 levels and when lesions were smaller. These findings indicate an early diagnosis of acromegaly at our institute. Further study is mandatory for the generalization of this trend.
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